381683-94-9

Efipladib (100 mg/kg; p.o.; BID for 31 days) reverses the severity in mouse collagen-induced arthritis (CIA) model^[1].
Efipladib (100 mg/kg; p.o.; once) significantly inhibits the nociceptive response 1 h after administration in the rat Complete Freund’s Adjuvant (CFA) nociception model^[2].
Efipladib is unable to cross the BBB to gain access to the central compartment^[2].
Efipladib (100 nM; IT; 5 μL) reduces PGE2 levels in the cerebrospinal fluid in rats^[2].